01—Abstract
Summary
Summary of the 8-K filed September 12, 2019. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on September 12, 2019, to disclose significant positive developments in its clinical pipeline.
The company announced positive interim results from its Phase 1 study for its cytomegalovirus (CMV) vaccine candidate, mRNA-1647. This represents a key step forward in developing a vaccine against a widespread and persistent viral infection.
Furthermore, Moderna reported positive Phase 1 results for its first systemic messenger RNA (mRNA) therapeutic, mRNA-1944, designed to encode a secreted protein. These dual positive updates from distinct therapeutic areas underscore the company's progress in advancing its mRNA platform across both vaccines and therapeutics, providing investors with encouraging clinical data and reinforcing the potential of its innovative technology.
02—Key points
Key Highlights
- Positive interim results announced for Phase 1 cytomegalovirus (CMV) vaccine study (mRNA-1647).
- Positive Phase 1 results reported for mRNA-1944, the first systemic mRNA therapeutic encoding a secreted protein.
- The announcements were made via press releases filed as exhibits to the 8-K.
- Moderna also held its 2019 R&D Day on September 12, 2019, with a related slide presentation filed as an exhibit.
- The information is furnished under Regulation FD, meaning it's not deemed 'filed' for Section 18 liability, but is important disclosure for investors.
- These developments signal progress in two distinct areas of Moderna's mRNA pipeline: vaccines and therapeutics.
03—Questions
Frequently Asked Questions
What are the key clinical updates provided by Moderna in this filing?
Moderna announced positive interim results from its Phase 1 study for its CMV vaccine candidate (mRNA-1647) and positive Phase 1 results for its first systemic mRNA therapeutic (mRNA-1944).
What is the significance of mRNA-1944?
mRNA-1944 is notable as it represents Moderna's first systemic messenger RNA therapeutic designed to encode a secreted protein, demonstrating the company's progress in developing mRNA-based therapeutics beyond vaccines.
Where can investors find more details about these announcements?
The detailed press releases announcing these results (Exhibits 99.1 and 99.2) and a slide presentation from the R&D Day (Exhibit 99.3) are attached to this Form 8-K filing and incorporated by reference.
Does this filing trigger any specific financial reporting changes?
No, this 8-K filing primarily serves as a disclosure of material information under Regulation FD. It announces clinical trial results and related presentations. Moderna has elected not to use the extended transition period for complying with new or revised financial accounting standards, as indicated by the absence of a checkmark.
04—Continue